A Pilot Study of the Safety and Efficacy of SEP-226330 in Subjects with Restless Legs Syndrome.
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2011
At a glance
- Drugs SEP 226330 (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- 14 Jun 2011 New trial record